Peptide Receptor Radionuclide Therapy in Patients With Neurofibromatosis Type 2: Initial Experience.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
pubmed:
8
4
2021
medline:
21
5
2021
entrez:
7
4
2021
Statut:
ppublish
Résumé
Neurofibromatosis type 2 (NF2) is a genetic disorder that is associated with multiple tumors of the nervous system, and approximately one half of patients present with meningiomas. For patients with multifocal disease, somatostatin receptor-targeted peptide receptor radionuclide therapy (PRRT) might be a suitable systemic treatment option. Between March 2015 and August 2017, 11 NF2 patients (7 females and 4 males; mean age, 39 ± 12 years) with multifocal, progressive meningiomas underwent a median of 4 cycles of PRRT (range, 2-6 cycles). Acute and chronic adverse events were recorded according to National Institutes of Health's Common Toxicity Criteria (CTC) version 5.0. Follow-up MRIs (every 3 to 6 months), using the Response Assessment in Neuro-Oncology response criteria for meningiomas, were used to assess treatment responses. Peptide receptor radionuclide therapy was well tolerated in all patients without any relevant acute adverse effects. Transient hematologic toxicity (CTC grade 3) was observed in 2 subjects. Somatostatin receptor-directed radiopeptide therapy resulted in radiological disease stabilization in 6 of 11 patients. Median progression-free survival was 12 months (range, 1-55 months), and overall survival was 37 months (range, 5-61 months). Based on our retrospective pilot data, PRRT is feasible and well-tolerated in NF2 patients. It might offer a suitable treatment option in subjects with multiple, recurrent, or treatment-refractory meningiomas.
Identifiants
pubmed: 33826573
doi: 10.1097/RLU.0000000000003627
pii: 00003072-202106000-00028
doi:
Substances chimiques
Receptors, Somatostatin
0
Octreotide
RWM8CCW8GP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e312-e316Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: This publication was funded by the Interdisciplinary Center of Clinical Research (IZKF) and the University of Würzburg in the funding program Open Access Publishing. None declared to all authors.
Références
Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis . 2009;4:16.
Hanemann CO. Magic but treatable? Tumours due to loss of merlin. Brain . 2008;131:606–615.
Lim SH, Ardern-Holmes S, McCowage G, et al. Systemic therapy in neurofibromatosis type 2. Cancer Treat Rev . 2014;40:857–861.
Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. J Neurooncol . 2010;99:341–347.
Perry A, Giannini C, Raghavan R, et al. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol . 2001;60:994–1003.
Lloyd SK, Evans DG. Neurofibromatosis type 2 (NF2): diagnosis and management. Handb Clin Neurol . 2013;115:957–967.
Wentworth S, Pinn M, Bourland JD, et al. Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int J Radiat Oncol Biol Phys . 2009;73:208–213.
Evans DG, Birch JM, Ramsden RT, et al. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet . 2006;43:289–294.
Osorio DS, Hu J, Mitchell C, et al. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2. J Neurooncol . 2018;139:749–755.
Mathew Thomas V, Bindal P, Vredenburgh JJ. Everolimus and bevacizumab in the management of recurrent, progressive intracranial NF2 mutated meningioma. Case Rep Oncol . 2019;12:126–130.
Reubi JC, Maurer R, Klijn JG, et al. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab . 1986;63:433–438.
Menke JR, Raleigh DR, Gown AM, et al. Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. Acta Neuropathol . 2015;130:441–443.
Rachinger W, Stoecklein VM, Terpolilli NA, et al. Increased 68 Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med . 2015;56:347–353.
Afshar-Oromieh A, Giesel FL, Linhart HG, et al. Detection of cranial meningiomas: comparison of 68 Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging . 2012;39:1409–1415.
Kunz WG, Jungblut LM, Kazmierczak PM, et al. Improved detection of transosseous meningiomas using 68 Ga-DOTATATE PET/CT compared with contrast-enhanced MRI. J Nucl Med . 2017;58:1580–1587.
Seystahl K, Stoecklein V, Schuller U, et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68 Ga-DOTATATE/-TOC uptake. Neuro Oncol . 2016;18:1538–1547.
Marincek N, Radojewski P, Dumont RA, et al. Somatostatin receptor-targeted radiopeptide therapy with 90 Y-DOTATOC and 177 Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med . 2015;56:171–176.
Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging . 2013;40:800–816.
Strosberg J, El-Haddad G, Wolin E, et al., NETTER-1 Trial Investigators. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med . 2017;376:125–135.
Bartolomei M, Bodei L, De Cicco C, et al. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging . 2009;36:1407–1416.
Norden AD, Ligon KL, Hammond SN, et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology . 2015;84:280–286.
Gerster-Gillieron K, Forrer F, Maecke H, et al. 90 Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas. J Nucl Med . 2015;56:1748–1751.
Hartrampf PE, Hänscheid H, Kertels O, et al. Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Clin Transl Radiat Oncol . 2020;22:29–32.
Verburg FA, Wiessmann M, Neuloh G, et al. Intraindividual comparison of selective intraarterial versus systemic intravenous 68 Ga-DOTATATE PET/CT in patients with inoperable meningioma. Nuklearmedizin . 2019;58:23–27.
Braat AJAT, Snijders TJ, Seute T, et al. Will 177 Lu-DOTATATE treatment become more effective in salvage meningioma patients, when boosting somatostatin receptor saturation? A promising case on intra-arterial administration. Cardiovasc Intervent Radiol . 2019;42:1649–1652.
Goutagny S, Raymond E, Esposito-Farese M, et al. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol . 2015;122:313–320.
Karajannis MA, Legault G, Hagiwara M, et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol . 2012;14:1163–1170.
Plotkin SR, Halpin C, McKenna MJ, et al. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol . 2010;31:1135–1143.